AU2008357065B2 - Herpes simplex virus (HSV) with modified tropism, uses and process of preparation thereof - Google Patents

Herpes simplex virus (HSV) with modified tropism, uses and process of preparation thereof Download PDF

Info

Publication number
AU2008357065B2
AU2008357065B2 AU2008357065A AU2008357065A AU2008357065B2 AU 2008357065 B2 AU2008357065 B2 AU 2008357065B2 AU 2008357065 A AU2008357065 A AU 2008357065A AU 2008357065 A AU2008357065 A AU 2008357065A AU 2008357065 B2 AU2008357065 B2 AU 2008357065B2
Authority
AU
Australia
Prior art keywords
modified
tumor
seq
modified hsv
homology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008357065A
Other languages
English (en)
Other versions
AU2008357065A1 (en
Inventor
Gabriella Campadelli
Laura Menotti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita di Bologna
Original Assignee
Universita di Bologna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita di Bologna filed Critical Universita di Bologna
Publication of AU2008357065A1 publication Critical patent/AU2008357065A1/en
Application granted granted Critical
Publication of AU2008357065B2 publication Critical patent/AU2008357065B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16633—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2008357065A 2008-05-29 2008-05-29 Herpes simplex virus (HSV) with modified tropism, uses and process of preparation thereof Ceased AU2008357065B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2008/000358 WO2009144755A1 (en) 2008-05-29 2008-05-29 Herpes simplex virus (hsv) with modified tropism, uses and process of preparation thereof

Publications (2)

Publication Number Publication Date
AU2008357065A1 AU2008357065A1 (en) 2009-12-03
AU2008357065B2 true AU2008357065B2 (en) 2013-07-25

Family

ID=40032777

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008357065A Ceased AU2008357065B2 (en) 2008-05-29 2008-05-29 Herpes simplex virus (HSV) with modified tropism, uses and process of preparation thereof

Country Status (11)

Country Link
US (2) US9157071B2 (enExample)
EP (2) EP2293804B1 (enExample)
JP (1) JP5683455B2 (enExample)
AU (1) AU2008357065B2 (enExample)
DK (2) DK2700405T3 (enExample)
ES (2) ES2667622T3 (enExample)
HU (1) HUE037311T2 (enExample)
NO (1) NO2700405T3 (enExample)
PL (2) PL2293804T3 (enExample)
PT (2) PT2700405T (enExample)
WO (1) WO2009144755A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9593347B2 (en) 2010-04-16 2017-03-14 University of Pittsburgh—of the Commonwealth System of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
KR102490462B1 (ko) 2013-10-28 2023-01-19 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 종양분해성 hsv 벡터
WO2020142677A1 (en) * 2019-01-03 2020-07-09 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
PT3256570T (pt) * 2015-02-11 2021-06-18 Univ Bologna Alma Mater Studiorum Herpesvírus redirecionado com fusão de glicoproteína h
ES2919953T3 (es) 2016-01-27 2022-07-29 Oncorus Inc Vectores víricos oncolíticos y usos de los mismos
AU2017276727B2 (en) 2016-06-09 2023-10-05 Alma Mater Studiorum Universita Di Bologna Herpesvirus with modified glycoprotein H for propagation in a cell
JP7185278B2 (ja) * 2016-06-09 2022-12-07 アルマ・マテール・ストゥディオルム・ウニベルシータ・ディ・ボローニャ 改変糖タンパク質ｂを有するヘルペスウイルス
EP3469071B1 (en) * 2016-06-09 2020-12-02 Alma Mater Studiorum -Universita' di Bologna Herpesvirus with modified glycoprotein d
CN109983121A (zh) 2016-06-30 2019-07-05 昂克诺斯公司 治疗性多肽的假型化溶瘤病毒递送
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
RU2771110C2 (ru) 2017-07-26 2022-04-26 Онкорус, Инк. Онколитические вирусные векторы и их применение
CN111051333B (zh) * 2017-08-30 2024-04-05 Km生物医薬股份公司 修饰型HSV gD蛋白及包含其的疫苗
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
US20210261649A1 (en) * 2018-06-29 2021-08-26 Krystal Biotech, Inc, Compositions and methods for antibody delivery
WO2020112471A1 (en) * 2018-11-28 2020-06-04 The Brigham And Women's Hospital, Inc. New generation regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use
WO2021101796A1 (en) * 2019-11-18 2021-05-27 The Brigham And Women's Hospital, Inc. Codon optimized new generation regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use
CN115803432A (zh) * 2020-06-12 2023-03-14 吉赛尔美德公司 用于重靶向的具有经修饰的糖蛋白gH的重组单纯疱疹病毒及其用途
CN112501137B (zh) * 2020-11-11 2023-10-20 深圳先进技术研究院 一种神经环路标记系统
EP4334439A1 (en) * 2021-05-05 2024-03-13 Janssen Biotech, Inc. Universal retargeting of oncolytic hsv
CN113969287B (zh) * 2021-10-22 2024-05-28 中国科学院深圳先进技术研究院 重组单纯疱疹病毒的亲和筛选细胞系及其构建方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
AU737910B2 (en) 1997-01-31 2001-09-06 Regents Of The University Of California, The Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
US6080399A (en) 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
AU2002256624B2 (en) 2001-02-19 2007-12-06 Merck Patent Gmbh Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
US20030007974A1 (en) 2001-05-30 2003-01-09 Nanus David M. Endopeptidase/anti-PSMA antibody fusion proteins for treatment of cancer
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
US20040115688A1 (en) 2002-04-19 2004-06-17 Cheung Irene Y. Detection of gd2 synthase mrna and uses thereof
US20070243170A1 (en) * 2002-10-07 2007-10-18 The University Of Chicago Targeting of Herpes Simplex Virus to Specific Receptors
US7501126B2 (en) 2002-10-07 2009-03-10 The University Of Chicago Targeting of herpes simplex virus to specific receptors
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
MX2008004693A (es) 2005-10-21 2008-09-03 Catalyst Biosciences Inc Proteasas modificadas que inhiben la activacion del complemento.
WO2007110231A2 (en) 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
WO2007149406A2 (en) 2006-06-19 2007-12-27 Nautilus Technology Llc Modified coagulation factor ix polypeptides and use thereof for treatment
GB0714578D0 (en) * 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Menotti, L. et al., Journal of Virology. 2006 vol. 80 no. 11 pages 5531-5539 *
Zhou, G. et al., Journal of Virology. 2003 vol. 77 no. 6 pages 3759-3767 *
Zhou, G. et al., PNAS. 2006 vol. 103 no. 14 pages 5508-5513 *

Also Published As

Publication number Publication date
AU2008357065A1 (en) 2009-12-03
US9157071B2 (en) 2015-10-13
DK2293804T3 (da) 2013-08-26
EP2293804A1 (en) 2011-03-16
JP5683455B2 (ja) 2015-03-11
HUE037311T2 (hu) 2018-08-28
PT2293804E (pt) 2013-08-29
US9744199B2 (en) 2017-08-29
NO2700405T3 (enExample) 2018-09-01
PL2293804T3 (pl) 2014-03-31
EP2700405B1 (en) 2018-04-04
US20110318268A1 (en) 2011-12-29
PL2700405T3 (pl) 2018-08-31
US20160074448A1 (en) 2016-03-17
PT2700405T (pt) 2018-05-02
DK2700405T3 (en) 2018-05-22
ES2425489T3 (es) 2013-10-15
EP2700405A1 (en) 2014-02-26
EP2293804B1 (en) 2013-05-22
ES2667622T3 (es) 2018-05-11
JP2011522532A (ja) 2011-08-04
WO2009144755A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
US9744199B2 (en) Herpes simplex virus (HSV) with modified tropism, uses and process of preparation thereof
US11419926B2 (en) Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
US20220056480A1 (en) Modified orthopoxvirus vectors
JP2023126868A (ja) 改変オルトポックスウイルスベクター
KR20210111237A (ko) 암세포 표적화 영역과 hvem의 세포외 도메인의 융합 단백질을 발현할 수 있는 발현 카세트를 가지는 재조합 헤르페스 심플렉스 바이러스 및 그 용도
KR20190015544A (ko) 변형된 당단백질 d를 갖는 헤르페스 바이러스
US12414973B2 (en) Antigenically stealthed oncolytic viruses
WO2008103762A1 (en) Targeting of herpes simplex virus to specific receptors
JP6025793B2 (ja) 親和性を改変した単純ヘルペスウイルス（ｈｓｖ）、その使用および調製法
JP2025526369A (ja) Ｐｄ－１／ｐｄ－ｌ１阻害剤を有するインターロイキン１２を発現する組換えウイルスの組み合わせ
HK1194678A (en) Herpes simplex virus (hsv) with modified tropism, uses and process of preparation thereof
HK1194678B (en) Herpes simplex virus (hsv) with modified tropism, uses and process of preparation thereof
Cerretani Molecular basis oh herpes simplex virus entry into the cell and retargeting of the viral tropism for the design of oncolytic herpesviruses
HK40030481A (en) Modified adenoviruses

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired